Next Article in Journal
A Targeted and Tuneable DNA Damage Tool Using CRISPR/Cas9
Next Article in Special Issue
Harnessing the Physiological Functions of Cellular Prion Protein in the Kidneys: Applications for Treating Renal Diseases
Previous Article in Journal
Irisin and Incretin Hormones: Similarities, Differences, and Implications in Type 2 Diabetes and Obesity
 
 
Article
Peer-Review Record

Involvement of Cellular Prion Protein in Invasion and Metastasis of Lung Cancer by Inducing Treg Cell Development

Biomolecules 2021, 11(2), 285; https://doi.org/10.3390/biom11020285
by Seunghwa Cha 1, Mi-Ji Sin 1, Mo-Jong Kim 2,3, Hee-Jun Kim 2, Yong-Sun Kim 2, Eun-Kyoung Choi 2,3,* and Mi-Yeon Kim 1,*
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Biomolecules 2021, 11(2), 285; https://doi.org/10.3390/biom11020285
Submission received: 18 January 2021 / Revised: 10 February 2021 / Accepted: 12 February 2021 / Published: 15 February 2021
(This article belongs to the Special Issue Prions and Prion-Like Mechanisms in Disease and Biological Function)

Round 1

Reviewer 1 Report

The manuscript covers an interesting topic describing the influence and role of prion protein on lung cancer invasion and metastasis. The authors demonstrate the important involvement in these processes of Treg Cells, whose growth is associated with high expression of PrP, which enhances cancer progression.

I provide minor comments below:
The introduction and the discussion should have been slightly more extended.
The authors should emphasise novelty even more clearly.
The authors should add a list of abbreviations.
I am curious about the authors' opinion as to why there was no effect of PrP expression on Natural Killer or CD8 T Cell numbers?

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Reviewer 2 Report

In this paper Seunghwa Cha and colleagues investigated the role of cellular prion protein (PrPC) in promoting cancer cell invasion and metastasis through the regulation of Treg development.

Overall, the manuscript is well written and the detailed data shed new lights on the possible interpretation regarding the involvement of PrPC in the pathophysiology of cancer progression and metastasis.

Within this frame, it would be interesting to know if the Authors have considered to extend the discussion regarding other PrP isoforms and/or PrP fragments. This is the case, for instance, of pro-PrP isoform, which has been recently discovered in human pancreatic ductal adenocarcinoma (PDAC) and melanoma cell lines. Being neither glycosylated nor GPI-anchored, pro-PrP retains the GPI anchor peptide signal sequence (GPI-PSS) which contains a filamin A binding motif, thus providing a growth advantage in these cell lines (Binding of pro-prion to filamin A disrupts cytoskeleton and correlates with poor prognosis in pancreatic cancer. Li C, Yu S, Nakamura F, Yin S, Xu J, Petrolla AA, Singh N, Tartakoff A, Abbott DW, Xin W, Sy MS. J Clin Invest. 2009 Sep; 119(9):2725-36; Pro-prion binds filamin A, facilitating its interaction with integrin beta1, and contributes to melanomagenesis. Li C, Yu S, Nakamura F, Pentikäinen OT, Singh N, Yin S, Xin W, Sy MS. J Biol Chem. 2010 Sep 24; 285(39):30328-39; The Role of Cellular Prion Protein in Promoting Stemness and Differentiation in Cancer. Ryskalin L, Biagioni F, Busceti CL, Giambelluca MA, Morelli L, Frati A, Fornai F. Cancers (Basel). 2021 Jan 6;13(2):170.).

A minor issue is to indicate “PrPC” when referring to “cellular prion protein” through the manuscript.

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Back to TopTop